Faron Pharmaceuticals, China Medical System deal

Faron granted China Medical rights in Taiwan and China, including Hong Kong and Macau, to develop and commercialize Traumakine ( FP-1201). Next quarter, Faron expects to start a European Phase III trial of the recombinant human interferon (IFN) beta-1a to treat severe and acute respiratory distress syndrome (ARDS). ...